Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide ... - BioSpace
Vivos Inc. initiates first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, successfully treating five cancer patients. The trial aligns with the protocol designed for the Mayo Clinic, focusing on safety. Vivos continues discussions with the FDA to initiate trials in the U.S., aiming to expand to 30 patients and publish comprehensive data in 2025.
Highlighted Terms
Related News
Vivos Inc. initiates first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, successfully treating five cancer patients. The trial aligns with the protocol designed for the Mayo Clinic, focusing on safety. Vivos continues discussions with the FDA to initiate trials in the U.S., aiming to expand to 30 patients and publish comprehensive data in 2025.